darbepoetin beta
Recombinant proteinexperimental
Epoetin beta (INN), sold under the brand name Neorecormon among others, is a synthetic, recombinant form of erythropoietin, a protein that promotes the production of red blood cells. It is an erythropoiesis-stimulating agent (ESA) that is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. — Wikipedia
Clinical trial activity
50 trials · 46 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
24
Phase 3
17
Phase 4
22
Earliest trial started May 1, 1998 (NCT00593801)
Timeline
Indications
Approved for
Studied for
- Anemia · Phase 4
- Chronic Kidney Disease-Mineral and Bone Disorder · Phase 3
- Diabetes Mellitus · Phase 3
- Dialysis · Phase 3
- Drugs, Generic · Phase 4
- Fatigue · Phase 2
- Hepatitis C · Phase 4
- Hepatitis C, Chronic · Phase 4
- HIV Infections · Phase 4
- Ischemia · Phase 3
- Kidney Diseases · Phase 4
- Kidney Failure, Chronic · Phase 4
- Kidney Transplantation · Phase 4
- Leukemia · Phase 3
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 3
- Lymphoma · Phase 3
- Lymphoma, Non-Hodgkin · Phase 3
- Multiple Myeloma · Phase 3
- Myelodysplastic Syndromes · Phase 4
- Myocardial Ischemia · Phase 2
- Neoplasms · Phase 3
- Renal Insufficiency · Phase 4
- Renal Insufficiency, Chronic · Phase 3
- Uterine Cervical Neoplasms · Phase 4
Mechanism of action
- Erythropoietin receptorAGONIST
EPOR agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEpoetin beta ↗
- ChEMBLCHEMBL2109092 ↗
Also known as
- 1-165-erythropoietin (human clone lamdahepofl13 protein moiety), glycoform beta
- bm 06.019
- epoch
- epoch
- epoetin beta
- epoetin beta
- epoetin beta
- epoetin beta
- epoetin beta
- epoetin beta
- epoetin beta (genetical rcombination)
- marogen
- neorecormon
- neorecormon
- neorecormon
- neorecormon
- neorecormon 1000
- neorecormon 10000
- neorecormon 2000
- neorecormon 20000
- neorecormon 3000
- neorecormon 30000
- neorecormon 4000
- neorecormon 500
- neorecormon 5000
- neorecormon 6000
- recombinant 1-165-erythropoietin glycoform beta
- recormon
- recormon 1000
- recormon 10000
- recormon 2000
- recormon 5000
- recormon s 1000
- recormon s 10000
- recormon s 2000
- recormon s 5000
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07119372 | Phase 3 | Mar 1, 2025 | Biocad |
| NCT03519243 | Phase 2 | Oct 24, 2017 | Biocad |
| NCT02791763 | Phase 3 | Jun 1, 2016 | GlaxoSmithKline |
| NCT03658876 | Phase 4 | Jun 3, 2015 | Imperial College London, University of London |
| NCT02876211 | Phase 4 | Dec 1, 2014 | Hospital Son Espases, Son Espases University |
| NCT02145026 | Phase 4 | Aug 31, 2014 | Roche |
| NCT01450878 | Phase 3 | Dec 1, 2011 | Roche, University of Limoges |
| NCT01364402 | Phase 3 | Aug 1, 2011 | Western Galilee Hospital |
| NCT01718379 | Phase 2 | Jul 1, 2010 | Celgene, Groupe Francophone des Myelodysplasies, Roche |
| NCT02428686 | Phase 2 | Jun 1, 2010 | Groupe Francophone des Myelodysplasies |
| NCT01111630 | Phase 4 | Oct 1, 2009 | Ilsan Hospital, JW Pharmaceutical |
| NCT00773331 | Phase 3 | Jul 1, 2009 | Roche |
| NCT01015352 | Phase 2 | Feb 1, 2009 | Celgene, Groupe Francophone des Myelodysplasies, Roche |
| NCT00773513 | Phase 4 | Dec 31, 2008 | Roche |
| NCT00717821 | Phase 3 | Oct 1, 2008 | Roche |
| NCT00628043 | Phase 3 | May 1, 2008 | Chugai |
| NCT00560274 | Phase 4 | Mar 1, 2008 | Roche |
| NCT00875004 | N/A | Dec 1, 2007 | University of Montpellier |
| NCT01085552 | Phase 1 | Nov 1, 2007 | InCROM |
| NCT00815867 | Phase 3 | Oct 1, 2007 | Roche, University of Paris, University of Picardie Jules Verne |
Showing 20 of 50 trials
Page 1 / 3
Organizations
Research & Development (46)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 28 | 21 | 4 | 1998 |
| Groupe Francophone des Myelodysplasies | Academic/Hospital | 3 | 3 | 1 | 2009 |
| Biocad | For profit | 2 | 2 | 2 | 2017 |
| Celgene | For profit | 2 | 0 | 1 | 2009 |
| Chugai | For profit | 2 | 2 | 1 | 2007 |
| University of Limoges | Academic/Hospital | 2 | 2 | 2 | 2005 |
| University of Picardie Jules Verne | Academic/Hospital | 2 | 2 | 2 | 2004 |
| AGO Germany | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Anemia Working Group | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Anemia Working Group Romania | Academic/Hospital | 1 | 1 | 1 | 2006 |
| Badalona Hospital Germans Trias i Pujol | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Barts & The London NHS Trust | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Carol Davila University of Medicine and Pharmacy | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Fundacio Lluita Contra la SIDA | Academic/Hospital | 1 | 0 | 1 | 2007 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2016 |
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 0 | 1 | 1998 |
| Hopital Antoine Beclere | Academic/Hospital | 1 | 0 | 1 | 1998 |
| Hospital Son Espases | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Humboldt University | Academic/Hospital | 1 | 1 | 1 | 1998 |
| IHS Dialysis Centre, Sf Ioan Nou Clinical Hospital | Academic/Hospital | 1 | 0 | 1 | 2006 |
46 organizations
Page 1 / 3